Immunity-Inducing Agent with Antigen Peptide-Adjuvant Nucleotide Conjugate

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12589148B2 to the University of Kitakyushu for an immunity-inducing agent comprising an antigen peptide-adjuvant nucleotide conjugate with CpG motif. The patent, filed September 27, 2019, contains 27 claims covering the pharmaceutical composition and methods for inducing immune responses. Pharmaceutical companies developing immunotherapeutic agents should evaluate potential licensing needs or design-around considerations.

View original document View source feed page

What changed

The USPTO issued Patent No. 12589148B2 to the University of Kitakyushu on March 31, 2026, covering an immunity-inducing agent and pharmaceutical composition containing 27 claims. Inventors Shinichi Mochizuki, Makoto Koizumi, and Koji Morita developed a peptide-nucleotide conjugate technology where a single-chain polynucleotide with CpG motif is covalently bound via a spacer to an antigenic peptide.

Pharmaceutical companies and drug manufacturers researching or developing immunotherapeutic agents should review this patent to determine whether their products or processes may infringe the granted claims. Parties interested in using this technology may need to pursue licensing arrangements with the University of Kitakyushu. No immediate compliance actions or deadlines are required as this is a patent grant rather than a regulatory requirement.

Source document (simplified)

← USPTO Patent Grants

Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same

Grant US12589148B2 Kind: B2 Mar 31, 2026

Assignee

The University of Kitakyushu

Inventors

Shinichi Mochizuki, Makoto Koizumi, Koji Morita

Abstract

The present invention provides an immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif, and an antigenic peptide are bound via a spacer, wherein the spacer is covalently bound at one end thereof to the polynucleotide or polynucleotide derivative and covalently bound at the other end thereof to the antigenic peptide, as well as a pharmaceutical composition comprising said immunity-inducing agent.